Meeting
2018 ASCO Annual Meeting
Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Authors
Cesar Serrano
Vall d’Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain
Cesar Serrano , Alessandro Leal , Jillian Phallen , Adrian Marino-Enriquez , Yanan Kuang , Olivia Triplett , Jeffrey A. Morgan , Constance Barysauskas , Andrew J. Wagner , George D. Demetri , Victor E. Velculescu , Cloud Paweletz , Jonathan A. Fletcher , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT02164240
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11510)
DOI
10.1200/JCO.2018.36.15_suppl.11510
Abstract #
11510
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2013 ASCO Annual Meeting
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2023 ASCO Annual Meeting
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
First Author: Jonathan C. Trent